Evidence map›Paper›PMID 25381477›Full record

ArticleHeart and vessels2016

Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention.

Tadanao Higaki, Satoshi Kurisu, Noriaki Watanabe, Hiroki Ikenaga, Takashi Shimonaga, Toshitaka Iwasaki, Naoya Mitsuba, Ken Ishibashi, Yoshihiro Dohi, Yukihiro Fukuda and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Observational
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tadanao HigakiDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Satoshi KurisuDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan. skurisu@nifty.com.
Noriaki WatanabeDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroki IkenagaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Takashi ShimonagaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Toshitaka IwasakiDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Naoya MitsubaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Ken IshibashiDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Yoshihiro DohiDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Yukihiro FukudaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Yasuki KiharaDepartment of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mean platelet volume (MPV) is a well-established marker of platelet activation, and recent studies have shown that platelet activation is central to the processes in the pathophysiology of coronary artery disease (CAD). The study population consisted of 45 patients with stable CAD who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents. We selected 45 age- and sex-matched control subjects without cardiovascular diseases who did not require antiplatelet therapy. Hematological test was performed 3 times within 1 month before DAPT (baseline), at 2 weeks after PCI (post PCI) and at 9 months after PCI (follow-up). Compared to control subjects, MPV was significantly larger in patients with CAD (10.0 ± 0.6 vs 10.7 ± 0.8 fl, p < 0.01) although there was no significant difference in white blood cell count, hemoglobin, and platelet count between the 2 groups. In patients with CAD, DAPT did not affect platelet count (19.3 ± 4.8 × 10(4)-18.9 ± 4.6 × 10(4)/μl) or MPV (10.7 ± 0.8-10.5 ± 0.9 fl) during the follow-up period. MPV remained to be higher at follow-up in patients with CAD despite DAPT compared to control subjects (10.1 ± 0.7 vs 10.5 ± 0.9 fl, p < 0.05). Our data suggested that MPV might not be suitable for monitoring the effects of DAPT on platelet activity in patients with CAD undergoing PCI.

Indexed as

Mean Platelet VolumePercutaneous Coronary InterventionAgedAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug-Eluting StentsDrug MonitoringDrug Therapy, CombinationFemaleHumansMalePlatelet ActivationPlatelet Aggregation InhibitorsPredictive Value of TestsAspirinClopidogrelPlatelet Aggregation InhibitorsTiclopidineCoronary artery diseaseDual antiplatelet therapyMean platelet volume

Identifiers

PMID25381477
OpenAlexW1990651270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.